Milestone for Ver-A-T1D
09. February 2022
On Monday February 8th, Medizinische Universität Graz celebrated the final visit of the very first participant in the Ver-A-T1D trial.
The blood pressure lowering drug Verapamil has shown to protect and strengthen beta cells and slowing down beta cell destruction in type 1 diabetes.
INNODIA is very thankful for the participant who's happy to remain in follow-up for the next 12 months. Congrats to the team!
![](/images/news/milestone_ver_a_1.jpg)
![](/images/news/milestone_ver_a_2.jpg)